OCTO-TELEMATICS
19.7.2021 09:02:15 CEST | Business Wire | Press release
OCTO Telematics, the leading insurance and fleet telematics services and analytics provider, today announced plans to hire more than 100 people as part of its ‘Smart Data, Smarter People’ program.
“Investment in top talent is indicative of the importance we place on continuous innovation to help organizations thrive by leveraging data and analytics to address fast-changing consumer needs”, said Paolo Codazzi, Group Chief HR & Organisation Officer, OCTO Telematics. “We are focused on developing our team with top talent from diverse cultural backgrounds that will not only be well versed in current and emerging technologies, but also in designing the mobility of the future.”
If the recruitment of ICT profiles mainly concerns the Rome office, the inclusion of commercial figures and those dedicated to business development concern other markets in which OCTO is growing, such as the United States and Europe. In addition to selected recent successful hirings in the United States, France, Switzerland, Spain and, last but not least, Italy we are pleased to announce that the OCTO’s Team in the UK is strengthened by the addition of 4 key leaders.
Vernon Bonser, joint OCTO Telematics as UK Commercial VP, after 21 years spent in the Fleet and Video Telematics market working, among others, for Cybit / Masternaut, Webfleet (formerly TomTom Telematics) and VisionTrack. Travis Kenny, as Sales Manager UK, joining with a strong background that includes Vision Track, Ryder System Inc and Tantalum Innovations.
Finally, two Global Stream Leaders, will be based out of the UK: Andy Walters as Global Stream Leader Fleet & Trucks and Henry Peacock as Global Stream Leader Industrial. The combined skillset and experience of these four leaders is the evidence of OCTO’s ambitious growth strategy.
Connected vehicle services amounted to US$400 billion in 2018 and may reach US$1 million by 2025. Between 2019 and 2030 the number of self-driving vehicles sold each year globally will increase from 50,000 to more than 18 million, revolutionising car use and the entire concept of mobility. OCTO’s ‘Smart Data, Smart People’ program will strengthen the company's technological and market leadership in connected services and solutions with an infusion of advanced technical skills in big data, data science, analytics and telematics. The talent will also bolster the company’s commitment to capabilities that advance OCTO’s Vision Zero (zero accidents, zero congestion, zero pollution) efforts globally.
About OCTO Telematics
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the Insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data generate actionable analytics, giving life to a new era of Smart Telematics. Today it has over 5.5 million connected users and the largest database of vehicle telematics data in the world, with over 290 billion miles of driving data collected and 485.000 claims and insurance events analyzed. It also manages over 400.000 vehicle rentals per month.
For more information, go to www.octotelematics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005038/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom